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A STUDY ON THE PROGNOSTIC EFFECTS OF HUMAN PAPILLOMAVIRUS AT 
HEAD AND NECK CANCER SUBSITES, & THE EFFECTS OF PATIENT SEX & 
AGE ON HPV-ASSOCIATED HEAD & NECK CANCERS. 
 
Hong Li, Yale University School of Medicine, New Haven, CT  
 
Head and neck cancers are the 6th most common solid cancer in the world. Human 
papillomavirus (HPV) infections are now accepted to be a previously unrecognized 
causative agent for head and neck squamous cell carcinomas (HNSCCs). However, 
research surrounding HPV’s effect at non-oropharynx sub-site is limited. There is also 
mixed literature over the prognostic effect of patient sex and age on overall survival in 
HNSCCs. We sought to utilize the National Cancer Database from 2004-2013 to evaluate 
the outcomes of the aforementioned objectives. Univariate and multivariate survival 
analyses were conducted with chi-square tests, Kaplan-Meier estimates, log-rank tests, 
and Cox proportional hazards multivariable modeling.  
 
The main findings of the study were:  
 
1. HPV-positive status was associated with survival at 4 tumor subsites: oral cavity 
(hazard ratio [HR], 0.76; 95% CI, 0.66-0.87), oropharynx (HR, 0.44; 95% CI, 





CI, 0.59-0.85). The HPV status was the greatest factor in survival outcome 
between the HPV-positive and -negative cohorts at the oropharynx subsite (77.6% 
vs 50.7%; survival difference, 26.9%; 95% CI, 25.6%-28.2%) and hypopharynx 
subsites (52.2% vs 28.8%; survival difference, 23.4%; 95% CI, 17.5%-29.3%). 
For the nasopharynx (HR, 1.03; 95% CI, 0.75-1.42) and sinonasal tract (HR, 0.63; 
95% CI, 0.39-1.01) subsites, HPV-positive status was not an independent 
prognostic factor.  
 
2. Though there were no significant differences in OS between the sexes in OP 
HPV-associated cancers, female sex was associated with worse OS in OP HPV- 
cancers (HR: 1.15; 95% CI 1.04–1.28, p = 0.004), whereas it was associated with 
improved OS in OC HPV-associated and HPV- cancers (HPV-associated: HR: 
0.71; 95% CI 0.50–0.99, p = 0.048; HPV-: HR: 0.87; 95% CI 0.78–0.95, p 
= 0.004).  
 
3. A younger age was independently associated with an improved OS in both OC 
and OPSCCs (OC- HR: 0.580; p<0.001; OP- HR: 0.556; p<0.001). Within the 
OPSCC group, age, however, still plays a secondary role to the effect of HPV 
(HPV-high risk serotype and young age significantly diminishes the chance of 







In conclusion, HPV positivity was associated with improved survival in 4 subsites 
(oropharynx, hypopharynx, oral cavity, and larynx), and the largest survival difference 
was noted in the oropharynx and hypopharynx subsites. In the nasopharynx and sinonasal 
tract subsites, HPV positivity had no association with OS. The effect of sex on OS in OC 
and OP SCC appears to vary based on tumor location and HPV status. Patients <40 years 
old have an improved OS compared to matched older controls.  
 
As clinicians, when treating individual head and neck patients, it is important to consider 
all aspects of the patient and their disease (its cancer sub-site, HPV-positivity status, sex 
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Head and neck cancers are the 6th most common solid cancer in the world, with over 
60,000 new cases a year.1 Human papillomavirus (HPV) infections are now accepted to 
be a previously unrecognized causative agent for head and neck squamous cell 
carcinomas (HNSCC).2 In the case of oropharyngeal squamous cell carcinomas (OPSCC), 
there has been as much as a 225% increase in HPV+ cancers between 1988 and 2004,3 
and up to 70% of new cases are caused by HPV.2,4,5 HPV+ OPSCC patients generally use 
less tobacco and alcohol, and are more likely to be younger than their HPV- 
counterparts.3,4 HPV+ status has a significant beneficial impact on prognosis, with one 
study reporting a 25% increase in survival at 3 years.6 HPV+ OPSCC responds more 
positively to radiotherapy, which may possibly be related to defects in double-strand 
break repair.7–9 This striking improvement has led to calls for de-intensification of 
treatment,10 which are currently being investigated.11–13 
 
OPSCCs are now hypothesized to behave distinctly compared to HNSCCs at other sites. 
HPV DNA has been discovered in tumors from other head and neck sites such as cancers 
of the oral cavity (OC).14–16 A recent study found that HPV-associated non-OPSCCs 









HPV’s effects at Different Cancer Sub-sites  
Investigation into non-OPSCC sub-sites, such as in the hypopharynx, nasopharynx, oral 
cavity, larynx, and sinonasal cavity, is relatively scarce. The literature that surrounds 
these other sub-sites is controversial. Studies revealed that HPV is present in these other 
sub-sites, albeit is estimated to be 5 times less prevalent in non-OPSCC than in 
OPSCC.15,18–21 A 2016 study compared the gene expression and DNA methylation 
profiles between HPV in non-OPSCC sites and OPSCC, and found them to be identical, 
leading authors to conclude that HPV can drive carcinogenesis in non-OPSCC.17 
Interestingly, the same study concluded that HPV-driven non-OPSCC have a distinct 
tumor microenvironment compared to that of OPSCC. Few studies have looked at the 
role of HPV at each individual non-OPSCC sub-site. Tumors of some sub-sites, 
particularly nasopharyngeal, are rare, and so accurately characterizing the prognostic 
effect of HPV has been difficult.  
 
HPV-associated HNSCCs in Women  
Despite HPV infection being common in both men and women, the incidence of HPV-
associated OPSCCs is more than two-fold higher among men than women.22 This sex-
specific finding raises questions regarding possible differences in the biological 
presentation of the cancer between men and women. To date, few studies have alluded to 
the sex-related differences in the prognosis for OPSCCs and other HNSCCs. One 
retrospective, multi-institutional study23 found sex to be a significant prognostic factor for 





same study found that in non-OPSCCs, sex did not have any prognostic significance for 
OS.  
 
HPV-associated HNSCCs in Young Patients  
With an epidemiological shift in HNSCC pathogenesis to a virally-mediated disease, the 
average HNSCC patient has also changed. HPV-positive HNSCC patients are more likely 
to be white, male, have a higher socioeconomic status, and have had minimal exposure to 
tobacco and alcohol.24–26 Furthermore, HPV-positive patients tend to be between 4 and 10 
years younger than their HPV-negative counterparts.24 It is an generally accepted that 
HPV-positive HNSCC has been shown to have better survival than HPV-negative 
cancers, 6,27–29 and, thus, a recent SEER study has shown an improvement in HNSCC 
prognosis in 2002-2006 compared to 1992 to 1996. This improvement held in all age 
groups, except for those over the age of 75.30 
 
As the average age of HNSCC patients falls,31 it is important to clarify differences in 
survival in order to better inform patients of their prognosis, and to better inform 
treatment plans. The existing literature has shown mixed results. Some have shown no 
difference in survival between younger and older patient,32–35 while some have shown a 







Statement of Purpose  
 
The purpose of this research is to provide an in-depth understanding of the outcomes of 
HPV-associated head and neck cancers through the use of a national, large sample 
obtained from the National Cancer Database (NCDB).  
 
In particular, the 3 main objectives of research are:  
• Objective 1: Examine the prognostic effect of HPV at all six HNSCC sub-sites  
• Objective 2: Determine the effect of patient sex (male vs. female) on the overall 
survival of HPV-associated and non-associated of OP and OCSCCs  
• Objective 3: Determine the effect of patient age (<40 years old vs. 40+ year olds) 
on the overall survival of HPV-associated and non-associated OP and OCSCCs  
 
It is our hope that the results of this study will further elucidate HPV’s role and 
importance as a prognostic tool at different head and neck sub-sites, and the role of 
patient sex and patient age within HPV-associated HNSCCs which ultimately may help 








Data were extracted from the NCDB from 2010 to 2014. The NCDB is a joint project of 
the Commission on Cancer (CoC) and the American Cancer Society.39 Cases are 
recorded from over 1500 accredited hospitals in the United States and Puerto Rico. The 
database represents over 70% of incidences of cancer in the United States. Each hospital 
that participates in the registry is responsible for submitting and tracking patient and 
tumor level data on patients with malignant neoplastic diseases. Data was analyzed 
accordingly to achieve the three research objectives (Figure 1).  
 
 




Objective 1 Objective 2 Objective 3
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Patient Population, Cancer Sub-sites and Histology Definitions 
Our study population includes patients whose primary malignancy was diagnosed as 
squamous cell carcinoma of the head and neck. The following Internal Classification of 
Disease for Oncology, Third Edition (ICD-O-3) histology codes were used for squamous 
cell carcinoma M8070-8073 and the following topography codes were used for 
oropharynx: C09.0-09.1, C09.8-09.9 (tonsil) C10.0, C10.2-10.4 (other oropharynx) and 
C-01.9 (base of tongue), for oral cavity cancer: C00.0-00.9 (lip), C02.0-02.4, C02.8-02.9 
(other/unspecified parts of the tongue), C03.0-03.1, C03.9 (gum), C04.0-04.1, C04.8-04.9 
(floor of mouth), C05.0-05.1, C05.8-05.9 (palate), C06.0-06.2, C06.8-06.9 
(other/unspecified parts of the mouth), for nasopharynx: C11.0-11.3, C11.8, C11.9 
(nasopharynx), for hypopharynx: C12.9 (pyriform sinus) and C13.0-13.2, C13.8, C13.9 
(hypopharynx), for sinonasal tract: C30.0, C30.1 (nasal cavity and middle ear) and 
C31.0-31.3, C31.8, C31.9 (accessory sinuses) and for larynx: C32.0-32.3, C32.8, C32.9 
(larynx).  
 
HPV Status Definition 
HPV status was available for cases diagnosed from 2010 to 2014 and was categorized as 
negative, positive for low-risk HPV types, positive for high-risk HPV types (HPV 16 
and/or 18), and HPV status unknown. Patients were classified as ‘HPV+’ (HPV-
associated) if they tested positive for high-risk HPV types, and ‘HPV-’ (HPV non-
associated) if they received a negative HPV test. Patients with low-risk HPV types or 






Patient Population Analysis 
We examined patient demographic and tumor data (age at diagnosis, race, 
Charleson/Deyo score, primary tumor site, American Joint Commission on Cancer 
(AJCC) T and N classification, tumor grade, primary treatment type, insurance status, 
median income quartiles, treatment facility type and location, and rural/urban 
classification of patient’s primary county of residence). Patients were excluded if they 
were younger than 18 years old, if AJCC TNM classification was unknown, or if primary 
treatment type was unknown. Primary treatment type was classified into the following 
groups: no treatment, radiation only, chemotherapy only, surgery only, radiation and 
chemotherapy, surgery and radiation, and surgery, radiation and chemotherapy. 
 
Statistical Analysis 
Data analyses were performed using SPSS 19.0 (IBM Corp., Armonk, NY). The 
comparison of mean age at diagnosis was analyzed using the Student’s t-test. 
Proportional distribution of race, primary tumor site, T and N classification, lymph node 
metastasis, primary treatment type, insurance status, median income quartiles, treatment 
facility type and location, and rural/urban classification of patient’s primary country of 
residence were compared using chi-squared tests. T-tests and chi-squared tests as 
described above were used to compare the distribution of characteristics between HPV+ 






Survival analysis was performed using Kaplan-Meier (KM) analysis. An unadjusted Cox 
proportional hazards regression model was used for multivariable survival analysis. Age, 
sex, race, T and N classification, Charleson/Deyo score, HPV status, primary treatment 
type, insurance status and median income were entered a priori into the model. A two-
sided p-value <0.05 was considered statistically significant.  
 
Specifics to Objective 1: Classification of HPV’s Association to Survival 
We utilized three tests to derive HPV’s association to improved survival among patients 
with HNSCC – 1) 5-year unadjusted survival rate, 2) KM survival curve analysis and 3) 
an unadjusted Cox proportional hazards regression model. Sub-sites where HPV-
positivity was found to have an association to improved outcome in the Cox model were 
further classified into “strong” or “moderate” association based on the size of the 
difference of 5-year unadjusted survival rates between HPV+ and HPV- cohorts. A 
difference of greater than >20% survival was classified as “strong” and a difference <20% 
was classified as “moderate”.  
 
Specifics to Objective 3: Propensity Score Matching (PSM) 
To balance the difference in basic clinical characteristics between young (<40 year old) 
and old (40+ years old) patients, we performed PSM. We performed matching on sex, 
race, primary treatment type, income, insurance status, AJCC T and N stage, 
Charlson/Deyo comorbidity index score, HPV status and primary tumor site (OC vs OP). 





difference between matched groups was satisfactory, KM 10-year OS survival curves and 
a Cox proportional hazards regression model were used for the matched dataset.    
 
Exemption Statement 
Our study is exempt from review by the Yale Human Research Protection Program 








Objective 1: HPV’s Effects at Different Cancer Sub-sites  
 
Baseline Characteristics 
We identified a total of 41,950 patients (16,644 with HPV+, 25,306 with HPV- tumors) 
with head and neck squamous cell carcinoma in the NCDB between 2010 and 2014 
(Figure 2). Baseline patient, hospital, clinical, and treatment characteristics by each sub-
site are shown in Table 1- Table 6. In general, HPV+ patients were more likely to be 
white, younger, male, present with earlier T staging tumors, and have poor differentiation 
on histology.  
 






Survival outcomes analyses 
5-year unadjusted survival rates and KM survival curves for each sub-site are shown in 
Table 7 and Figure 3 respectively. Large survival differences were noted in the 
oropharynx and hypopharynx between HPV+ and HPV- patients (OP: 77.6% vs. 50.7% 
(Δ 26.9%, 95 CI 25.6%-28.2%); HP: 52.2% vs. 28.8% (Δ of 23.4%, 95% CI 17.5%-
29.3%)) between HPV+ and HPV- patients respectively.  
 
Smaller survival differences were found between HPV+ and HPV- patients in oral cavity, 
larynx, and sinonasal tract sub-sites (OC: 59.4% vs. 53.1% (Δ 6.3%, 95% CI 3.3%-9.3%); 
LRX: 57.2% vs. 48.7% (Δ 8.5%, 95% CI 5.1%-11.9%), SNT: 63.1% vs. 45.1% (Δ 18.0%, 
95% CI 8.7%-27.3%)). No statistically significant survival difference was noted in the 








Figure 3. Kaplan-Meier survival curves by HPV status. Unadjusted hazard ratios (HR) for HPV status and its associations 






On multivariate analysis, HPV+ status remained an independent prognostic factor for the 
oral cavity, oropharynx, hypopharynx, and larynx sub-sites (OC: HR 0.76, 95% CI 0.66-
0.87, OP: HR 0.44, 95% CI 0.41-0.47, HP: HR 0.59, 95% CI 0.45-0.77, LRX: HR 0.71, 
95% CI 0.59-0.85) after accounting for age, sex, race, Charleson/Deyo comorbidity score, 
insurance, income, T and N staging, and primary treatment. For the nasopharynx and 
sinonasal tract sub-sites, HPV+ status was not associated with increased overall survival 
(NP: HR 1.03, 95% CI 0.75-1.42; SNT: HR 0.63, 95% CI 0.39-1.01).  
 
Other factors associated with survival at each sub-site are shown in Table 8-Table 13. 
Having any treatment other than chemotherapy alone was associated with improved 
survival in five of six sub-sites. The HRs ranged between 0.07-0.7 and the 95% CIs did 
not include unity (1.0) when comparing treatment groups to baseline no treatment. 
Interestingly, having chemotherapy alone did not improve the hazard of death in five of 
the six sub-sites (HR ranged between 0.8-1.1 and 95% CI included unity). Having a score 
of 2 on the Charlson/Deyo score is associated with worse survival at all sub-sites (HRs 
ranged between 1.4 and 2.1 and 95% CI were larger than unity).  
 
 
Objective 2: Effects of Sex on HPV OP and OCSCCs 
 
Baseline Characteristics 
Our study population (n=30,707) included 13,694 OP HPV-associated; 7,933 OP HPV- 







Figure 4. CONSORT diagram of total study population (n=30,707), patient selection and exclusion. 
 
The presence of HPV was correlated with higher proportion of disease burden among men. Among the OP HPV-associated 
and HPV- cohorts, 86.2% and 76.3% of patients were men respectively. Among the OC HPV-associated and HPV- cohorts, 
76.3% and 59.8% were men respectively. Each group was further analyzed for baseline characteristic differences by sex 
(Table 14 and  






Within all four groups, women were on average older at age of diagnosis (p<0.001 for 
each group). Women were generally diagnosed with cancers in earlier T and N clinical 
classification than men. In OP, this difference was most pronounced in N classification; 
in OP HPV-associated cancers, 39.4% women vs. 27.2% men had N0-1 cancers 
(p<0.001), in OP HPV- cancers, 50.0% women vs. 39.9% men had N0-1 cancers 
(p<0.001). In OC HPV-associated cancers, 40.1% women had T0-1 cancers vs. 29.8% 
men and in OC HPV- cancers (p=0.005), 42.3% vs. 34.8% in women and men 
respectively (p<0.001). Women in all four groups were more likely to be treated with a 
modality including surgery (surgery only, surgery and radiation, or surgery and chemo-
radiation; p<0.001 in each group). For insurance coverage, more women were covered by 
Medicare than men across all four study populations. 
 
Factors associated with survival in OPSCCs 
Kaplan-Meier survival analysis showed no difference in OS between the two sexes in OP 
HPV-associated cancers (p=0.64; Figure 5a). On multivariate analysis, after accounting 
for age at diagnosis, ethnicity, clinical T and N classification, primary disease site, 
primary treatment, insurance status and median income, female sex (HR: 0.93; 95% CI 
0.79-1.009, p=0.412) did not prove to be an independent prognostic factor for OS.  
 
In OP HPV- cancers, men had a statistically significant better OS than women on Kaplan Meier survival analysis (p=0.035, 
Meier survival analysis (p=0.035, Figure 5b). In multivariate analysis, female sex (HR: 1.15; 95% CI 1.04-1.28, p=0.004) 





worse OS in OP HPV- cancers even after controlling for other variables (as described previously,  
Table 16).  
 
The hazard of death was notably higher for both OP HPV-associated and HPV- cohorts with increasing age, higher T and N 
classification, cancers at sites other than base of tongue or tonsils and patients with no primary treatment ( 
Table 16).  
 
Factors associated with survival in OCSCCs 
Kaplan-Meier survival analysis showed that among OC cancers, women had better OS 
than men in both HPV-associated and HPV- cancers (p=0.049, p<0.001 respectively, 
Figure 5c,d).  
 
In contrast to the varying prognostic roles of female sex in OPSCCs, in OCSCCs, female 
sex remained a strong prognostic factor for better OS in both HPV-associated and HPV- 
cancers (HPV-associated: HR: 0.71; 95% CI 0.0.50-0.99, p=0.048; HPV-: HR: 0.87; 95% 
CI 0.78-0.95, p=0.004;  Table 17) after controlling for over variables. In OC HPV-
associated cancers, age (HR: 1.02; 95% CI 1.00-1.04, p=0.01) and black race (HR: 1.88; 
95% CI 1.14-3.11, p=0.013) were significant predictors of OS in patients. In OC HPV- 
cancers, age (HR: 1.02; 95% CI 1.02-1.02, p<0.001), N classification (p<0.001) and 
having higher median income $63,000+ ((HR: 0.77; 95% CI 0.67-0.88, p<0.001), and 
having treatment (over no treatment; p<0.001 for all except chemotherapy only group 







Figure 5. Kaplan-Meier survival and number at risk a) OP HPV-associated: p=0.638, b) OP HPV negative: p=0.035, c) OC 
HPV-associated: p=0.049, d) OC HPV negative: p<0.001. 
 
Objective 3: Effects of Age on HPV OP and OCSCCs 
 





After exclusion, we identified 155,359 total patients, of which 3,749 (2.4%) were 
included in our younger cohort (ages 18 to 39) and 151,610 (97.6%) were included in our 
older cohort (ages ≥40). The mean age was 33.8 years and 62.3 years for our younger and 
older cohort, respectively (p<0.001). While there was a male predominance in both 
cohorts, the younger cohort had a significantly larger proportion of females (36.6% vs. 
27.2%; p<0.001). The younger cohort also had less whites (86.2% vs. 89.1%; p<0.001), 
had higher rates of private insurance (64.2% vs. 42.3%; p<0.001), a lower comorbidity 
burden (CDCC score of 0; 92.5% vs. 80.6%; p<0.001), tended to have a higher number 
of people with an income of over $48,000 a year (58.7% vs. 56.8%; p=0.036), and a 
larger proportion of people living in metro areas (83.5% vs. 81.9%; p=0.027) (Table 18). 
 
Oncologically, younger patients were more likely to present with oral cavity cancers 
(66.20% vs. 44.4%; p<0.001) in their early stages (T1: 45.4% vs. 37.1% [p<0.001]; N0: 
68.1% vs. 59.3% [p<0.001]) than their older counterparts, though they were less likely to 
test positively for high-risk HPV subtypes (7.1% vs .9.7%; p<0.001). Younger patients 
were more likely to undergo surgery (37.5% vs. 26.4%) or surgery with CRT (24.9% vs. 
15.2%), but less likely to obtain CRT alone (20.5% vs. 35.7%; p<0.001) (Table 19). 
 
As shown in Table 18 and Table 19, after propensity score matching was performed, no 
differences were seen in any patient characteristic, with the exception of mean age. Post-







Figure 6. CONSORT diagram of total study population (n=155,358) and post-match sample by age group (n=3,510 in each 
cohort), patient selection and exclusion. 
 
Primary Sub-site of Tumor 
Younger patients were more likely to obtain cancer in a tongue (not base of tongue) sub-
site (49.4% vs. 17.7%), while older patients were likely to have a tumor in the base of 
tongue (23.5% vs. 12.0%) or tonsil (25.4% vs. 19.1%; p<0.001). After propensity score 
matching, these differences were less pronounced, though still statistically significant 
(p<0.001) (Table 20). 
 
Overall Survival Difference by Age 
On Kaplan-Meier analysis of the overall study population, the young cohort had better 5-
year survival than the older cohort. 5-year survival was 82.8% [SE: 0.8%] for the 
younger cohort and 72.2% [SE: 0.9%] in the older cohort, Log-Rank p<0.001 (Figure 7).  




Young Patients  
18-39 years old 
(n=3,749) 
Older Patients  




Excluded: (n= 77,557) 
• Age <18 (n=305) 
• No primary treatment recorded (n=3,961) 
• No TNM classification data (n=49,197) 
• Non-squamous cell carcinoma (n=24,094) 







Figure 7. Kaplan-Meier survival curve and number at risk of overall study population (post-Propensity Score Match) 
 
Survival Differences by Age in the Oral Cavity 
When looking at the prognostic effect of age at specific oral cavity sub-sites in our 
matched cohort, we found that the younger cohort was associated with a higher survival 
than the older cohort in non-base tongue (p=0.034) and palatal tumors (p<0.001). 5-year 
survival was 78.2% [SE: 1.2%] for the younger cohort and 74.0% [SE: 1.5%] in the older 
cohort for tongue (non-base of tongue) sub-sites (Figure 8a). Similarly, 5-year survival 
was 96.3% [SE: 1.1%] for the younger cohort and 67.4% [SE: 3.5%] in the older cohort 
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mouth sub-sites (young cohort: 5-year survival was 73.9% [SE: 5.6%]; older cohort: 5-
year survival was 64.9% [SE: 3.0%]; p=0.314) (Figure 8b).  
 
Upon multivariate cox analysis controlling for sex, race, AJCC T and N stages, HPV 
status, treatment, and tumor sub-site, we found that a younger age was independently 
associated with an improved survival (HR: 0.580; p<0.001). Of note, we found that floor 
of mouth cancers were associated with increased mortality compared to lip tumors (HR: 
1.447; p=0.029). RT alone was found to have no improvement in survival when 
compared to no treatment at all (HR: 0.597; p=0.6639). The full regression may be found 
Table 21.  
 
Survival Differences by Age in the Oropharynx 
 
When looking at the prognostic effect of age at specific oropharynx subsites in our 
matched cohort, we found that the younger cohort was associated with a higher survival 
than the older cohort in tonsillar tumors (p=0.003). 5-year survival was 86.8% [SE: 1.9%] 
for the younger cohort and 77.3% [SE: 2.5%] in the older cohort for tonsillar tumors 
(Figure 9b). However, such a survival difference was not noted for base-of-tongue tumors 
(p=0.330). 5-year survival was 76.4% [SE: 2.7%] for the younger cohort and 73.3% [SE: 
3.0%] in the older cohort for tongue tumors (Figure 9a). 
 
In the multivariate cox model, age continued to be associated with a positive prognostic 





improved survival (HR: 0.397; p=0.011). Compared to tumors at the base-of-tongue, 
tonsillar tumors were associated with increased survival (HR: 0.707; p=0.006). The full 
regression may be found in Table 21. 
 
 
Figure 8. Kaplan-Meier survival curves and number at risk of selected oral-cavity sub-sites post-Propensity Score Match (a) 
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b. Floor of Mouth (Post-Match)
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Figure 9. Kaplan-Meier survival curves and number at risk of selected oropharynx sub-sites post-Propensity Score Match (a) 
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269 236 191 155 122 101
287 255 213 167 136 116Young
Old
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We present the largest and most comprehensive retrospective study examining 1) the role 
of HPV and its association to overall survival at all head and neck sub-sites, 2) the role of 
sex and 3) the role of age in HPV-associated oral cavity and oropharynx tumors.  
 
In our study, with respect to objective 1 - we found HPV to have a strong association 
with overall survival in the oropharynx and hypopharynx, moderate association with 
improved survival in the oral cavity and larynx, and no effect in the nasopharynx and 
sinonasal tract.  
 
Given that HNSCCs affect the two sexes disproportionately (80% men)22, we 
hypothesized that sex will be a prognostic factor for survival in HNSCCs. With respect to 
objective 2 - our study found that sex does appear to play a distinct role in predicting OS 
and that the prognostic value of sex is dependent on HPV status and location of primary 
tumor. 
 
Finally, as the average age of HNSCC patients falls,31 we hypothesized that young 
patients, specifically those between 18-39 years old, would have better OS than older 
patients (40 years or older). Based on our findings for objective 3, young age indeed is 
prognostic of better OS in both oral cavity and oropharynx sub-sites. Interestingly, 
contrary to existing literature,35,40 even for tumors of the tongue (not base of tongue) sub-






The following sections of the discussion address each research objective separately 
followed by a summative section addressing the limitations of this research with respect 
to the use of the NCDB.  
 
HPV’s effects at Different Cancer Sub-sites  
The results of our study, suggesting a variance in the magnitude of survival benefit 
depending on sub-site, provide a foundation for further study. It is unknown why HPV 
plays a bigger prognostic role in the oropharynx and hypopharynx than in the oral cavity 
and larynx. Perhaps it is because anatomy and function of each sub-site differs 
substantially. This theory may partly explain the similarity in HPV’s role between the 
adjacent oropharynx and hypopharynx. Preclinical studies alluded to differences in the 
micro-tumor environment between OPSCC and non-OPSCC.17 This may explain the 
contrast seen between the oral cavity/larynx and oropharynx/hypopharynx sites.  
 
Recent studies have found that mutations in TRAF3 and CYLD occur only in HPV-
associated HNSCC41 and correlate with survival.42,43 The absence of viral genome 
integration is also associated with improved survival44, and was predicted by mutations in 
TRAF3 or CYLD.43 Together, these data suggest that HPV carcinogenesis can occur 
through HPV integration or through maintenance of the HPV episome,43 and that tumors 
lacking HPV integration have improved survival. Future studies will be required to 





and have HPV integration, which could explain why HPV is not associated with as large 
a survival advantage in these sub-sites. 
 
The sinonasal tract is unique in that it may be at lower risk of exposure to HPV. It is 
hypothesized that oral HPV infection is transferred by oral sexual contact.45 However, it 
is not known if high-risk sexual behavior also affects cancers of the sinonasal tract. A 
histological analysis of 131 sinonasal carcinomas found high-risk HPV DNA in 21% of 
tumors.46 Interestingly, though non-keratinizing squamous cell carcinoma was found to 
be the most common histologic type, the study also reported multiple tumors that were 
basaloid, papillary, and adenosquamous variants, and some that contained features of a 
salivary gland neoplasm. This study, in combination with our results, suggests that 
sinonasal carcinomas confer distinct biological and clinical characteristics worthy of 
further investigation. 
 
Though HPV’s prognostic role in oropharynx cancers is well established6, there is now an 
emerging body of conflicting evidence regarding its role in other sites of the head and 
neck.14,16,23,47–50 The majority of studies investigating the prognostic effect of HPV at 
each non-OPSCC sub-site suffered from small sample sizes and report varied results.51–53 
Many trials have reported the strong association of p16 with improved progression 
survival, OS, and relapse-free survival in oral cavity, hypopharyngeal, and laryngeal 
cancers.14,47–49 Some studies have grouped together all non-OPSCC subtypes, as opposed 
to delineating the effect by sub-site. The results of such studies range from minimal 






Our data is supported by a recent study by Ko and colleagues that examined the role of 
HPV at non-OP subsites (oral cavity, hypopharynx, and larynx).50 The investigators 
aggregated the three sub-sites and examined the two cohorts based on disease staging (I 
& II, and III & IV). Favorable prognosis was identified in both groups for HPV+ patients. 
However, their analysis did not specifically examine the role of HPV at each sub-site by 
running a multivariate analysis for each sub-site cohort, though KM studies were done by 
sub-site. Our study more thoroughly examined the effect of HPV as we isolated patient 
cohorts by sub-site to determine the role of HPV. In this way, we were able to exclude 
effects of interactions between the primary location of the tumor and HPV status on 
overall survival.  
 
Though our study and many others have found improved outcomes associated with 
HPV+ non-OPSCC, two studies exist to the contrary. One recent two-institutional pooled 
analysis found no survival advantage for patients with larynx, oral cavity, and 
nasopharynx cancers.23 Another study utilizing the Danish Head and Neck Cancer Group 
database comparing advanced p16 and non-p16 tumors in larynx and hypopharynx 
tumors demonstrated no outcome differences.16 These contrasting results may be due to a 
difference in patient population (median age, sex distribution, race, and inclusion criteria) 
between the aforementioned studies and our own. In addition, their utilization of p16 as a 






The role of HPV in nasopharynx is still controversial. One study with 90 patients (9 
HPV+ cases) found survival benefit with HPV+ tumors,54 while another recent study with 
125 patients (13 HPV+ cases) found no survival benefit with HPV+ tumors.23 One case 
series of 45 cases found that HPV+ nasopharyngeal tumors may represent primary 
oropharyngeal tumors with extension to the nasopharynx site.55 This is one of the largest 
studies examining the role of HPV in nasopharyngeal cancers. Though we found no 
survival benefit associated with HPV+ NP tumor status, given the retrospective and 
database nature of this study, we were unable to determine the level of primary site 
misclassification. Historically, the role of the Epstein-Barr virus (EBV) has been well 
characterized in the pathogenesis of nasopharynx tumors. The role of EBV and its 
interaction with HPV were outside the scope of our study and not captured by the NCDB; 
data suggest that EBV-associated nasopharyngeal cancers have improved prognosis 
compared to virus-negative tumors,56 which could confound the analysis of the effect of 
HPV status.  
 
In summary, we identified a variance in the role of HPV and its association with 
outcomes in head and neck tumors. Though HPV+ status improved disease survival 
outcomes for four sub-sites, the greatest magnitude of its effect is most noted at the 
oropharynx and hypopharynx subsites. HPV does not appear to affect the prognosis for 
the nasopharynx and sinonasal tract sub-sites. Given these results, we recommend routine 
testing for HPV status in HNSCC at the oropharynx, hypopharynx, oral cavity, and 






HPV-associated HNSCCs in Women  
HPV status and its importance as a prognostic marker in oropharyngeal SCCs has been 
well established.6,57 The prognostic associations of HPV status with other clinical factors 
such as sex and primary tumor location have not been well investigated. Given that 
HNSCCs affect the two sexes disproportionately (80% men), we hypothesized that sex 
will be a prognostic factor for survival in HNSCCs. Our study found that sex does appear 
to play a distinct role in predicting OS and that the prognostic value of sex is dependent 
on HPV status and location of primary tumor. This finding is consistent with the idea that 
HPV-driven cancers in non-OP locations exhibit distinct clinical behavior and possess 
unique risk factors than HPV-driven cancers in OP.17,23  
 
Molecular underpinnings of the HPV infection between the two sexes also vary. One 
Finnish study examining the clearance of HPV DNA using oral rinses between spouses 
found earlier virus clearance in men than in women as well as significantly different 
cumulative clearance rates (5% vs. 0% clearance in men and women respectively over 24 
months).58 In a long-term prospective 6 year study of asymptomatic HPV infections, 
Syrjänen and colleagues found a 5.5 fold number of viral HPV copies in women than in 
men who were able to clear the infection.59 Although similar copy numbers were found 
between sexes for those with persistent infections, 71% of the HPV DNA was integrated 
or mixed in women vs. 57% in men. Full integration of the HPV episome into human 
chromosomes has been shown to be an early event in cervical carcinogenesis,60,61 though 





distinction in HPV’s molecular behavior between sexes that needs to be further 
categorized.  
 
Prior studies have been inconclusive on the significance of sex as a prognostic marker for 
overall survival. A recent two-institution retrospective study found sex to be prognostic 
in OPSCCs even after accounting for HPV-status.23 The authors examined 860 patients 
with OPSCCs (including HPV-associated and HPV- patients) and performed a 
multivariate regression model. Our study utilizes more targeted patient subgroups that 
specifically examines the role of sex among HPV-associated or HPV- patients. To our 
knowledge, our study is the largest study with patients and their HPV status spanning 
across the entire U.S. As a result, our sample provides the power for the subgroup 
analyses for the detection of differences in sex. However, due to the nature of the national 
cancer registry, there is inherent uncertainty to the nature of our data as the quality of the 
data relies on the accuracy of data entry, diagnosis and treatment at over 1500 hospitals. 
In comparison, Fakhry et al.’s two-institution study limits their data inaccuracies due to a 
smaller sample size.  
 
Existing research has shown that women have a significant survival benefit in many 
cancers outside of the head and neck region.62 However, for HPV- OPSCCs, we found 
the opposite where men have better survival than women. This similar trend also exists in 
patients with bladder cancer.63,64 The reason for this observed survival advantage is 
unknown. Preclinical studies support a role for sex hormones as cofactors for HPV-





this unique sex-specific finding. One study found the progesterone antagonists and 
nuclease-resistant oligomers containing HPV-16 response element are able to abrogate 
cell growth and E6/E7 gene transcription.65 Another study examining HPV-induced 
laryngeal tumors found estradiol stimulated proliferation while 2-hydroxyestrone was 
anti-proliferative.66 Both preclinical studies found hormonal interactions using HPV-
associated tumor models, thus this does not fully explain our findings in the HPV- 
OPSCC cohort. Perhaps there exists an interaction between HPV and sex hormones in the 
OP sub-site, which improves the survival of women thus equalizing overall survival 
between the two sexes. Nonetheless, we acknowledge the proximity of the Kaplan-Meier 
survival curve between the two sexes in the HPV- OPSCC cohort. Given the absence of 
tobacco and alcohol data, it is possible that the two sexes may have no survival difference 
in HPV- OPSCCs.  
 
Interestingly, in our OCSCC study population, women were shown to have better 
survival than men in both the HPV-associated and HPV- group. This finding contrasts 
with the role that sex plays in OPSCCs and is consistent with the developing hypothesis 
that OP and non-OP SCCs are distinct cancers. Risk factors for OCSCC are well 
established: alcohol, tobacco and betel nut chewing.67,68 Current rates of tobacco usage in 
the US are lower in women than in men.69 As a result, a lower overall lifetime exposure 
to tobacco may partly explain the survival advantage among women in OCSCC. There is 
a new growing body of research interested in characterizing HPV in non-OP sites. A 





associated OP and non-OP sites found there to be two distinct tumor immune 
microenvironments.17   
 
While our study did not directly test for the role of HPV within the OCSCC group, the 
similarity in risk factors between the HPV-associated and HPV- OCSCC groups infers 
that HPV may only play a minor prognostic role in OC cancers. A recent study by our 
group28 found HPV to be associated with improved survival at the OCSCC subsite, 
though the survival advantage noted at the oral cavity subsite was not as great as that at 
the oropharynx subsite.  
 
In our study, we found women were generally diagnosed with earlier T and N staged 
cancers than men. Earlier detection of cancers would lead to better prognosis.70 From a 
health behavior perspective, this finding may be explained by the consistent 
underutilization of preventative healthcare by men leading to a delay in early 
diagnosis.71,72 It has been hypothesized that women have more frequent contact with 
healthcare professionals due to pregnancy, childcare and hormone replacement therapy as 
well as women having more interest in health.71,73  
 
In summary, the effect of sex on outcomes of OP and OC SCCs appears to vary based on 
primary tumor location and HPV status. Notably, sex does not appear to affect the 
prognosis of HPV-associated OPSCCs after accounting for other risk factors. Men with 
HPV- OPSCCs appear to have a better prognosis for survival than women, though 





these results, we recommend further studies to investigate the clinical behavior and the 
sex-specific pathophysiological biology of HPV-associated HNSCCs and explore 
opportunities to further eliminate disparities in our patients.  
 
HPV-associated HNSCCs in Young Patients  
This study is the largest national study comparing the outcomes of oral cavity and 
oropharynx SCCs in young patients. As the average age of HNSCC patients falls,31 we 
hypothesized that young patients, specifically those between 18-39 years old, would have 
better OS than older patients (40 years or older). Our study suggests that young age 
indeed is prognostic of better OS for SCCs at both oral cavity and oropharynx sub-sites. 
In addition, young patients were also found to have better 5-year and 10-year OS in oral 
tongue SCCs that their older counterparts.  
 
We used a propensity score match analysis to evaluate the survival difference between 
the two age groups. Our results strongly suggest that young age is associated with 
improved survival in both OC and OP SCCs. Currently, there is much debate surrounding 
the prognostic value and appropriate management of young patients with OCSCCs. Older 
studies of small samples of young patients have predominantly found worse prognosis 
and called for more aggressive treatment in young patients with OCSCCs.74–76 However, 
more recent studies, though still single-institution or with small sample sizes have found 






While we were unable to assess locoregional recurrences due to data capture restrictions, 
a few studies have found young patients to have higher locoregional recurrence rates 
without any corresponding difference in OS when compared to older patients.33,40,81 
 
Pre-matched pair analysis, our sample showed young patients to present with earlier 
clinical T and N staging (45.4% vs 37.1% in T1 and 68.1% vs. 59.3% in N0). In addition, 
there were more women among the younger cohort (36.6% vs 27.2%) and young patients 
were more likely to present with OC tumors. Based on previous findings from our group, 
women, irrespective of HPV-status, performed better than men at the OC sub-site.82 
These findings, combined, may partially explain the mechanisms underlying age and its 
prognostic effects on OS at OC and OP sub-sites.  
 
A recent single institution, small UK study (n=50) examining the clinicopathological 
features of OC and OPSCCs in young patients (<45 years old) matched to older patients 
found similar disease profile in terms of tumor sub-site distribution and similar 
conventional risk factors profiles including tobacco and alcohol use between the two age 
groups.83 The study also suggests that existing prognostic and treatment paradigms for 
the treatment of OC and OPSCCs is likely applicable to young patients as well. Our study, 
in contrast, found varying distributions of tumors between the two age groups. Almost 
half (49.4%) of our young patient cohort presented with oral tongue cancers (vs. 17.7% in 






Within OCSCCs, we are seeing both a global and US trend of increasing incidence of 
oral tongue SCCs (OTSCCs) in young adults.84,85 Though we do not fully understand the 
mechanism underlying this increase, nonetheless, this has become an increasingly 
important public health issue. Prognosis of young adults with OTSCCs and their clinical 
progression remains an area of debate as multiple studies have reported varying 
(equivalent, worse or better) prognosis when compared to their older counterparts.86–89 
Most recently, Mukdad et al. found that, using a national US registry between 1973-2002, 
young patients with OTSCCs have improved survival rates.80 Our study supports this 
finding as a sub-analysis of the OTSCC sub-site found young patients to have better OS 
at both 5-years (78.2%) and 10-years (74.1%). As our study only examined NCDB data 
from 2004-2013, improvements in the treatment of OTSCCs within the last 15 years may 
explain the higher 5-year and 10-year OS as compared to the Mukdad et al. results (53.7% 
and 38.4% respectively).  
 
At the OP sub-site, our study continued to find young age to be a prognostic indicator for 
overall survival. As HPV is now widely believed to play a significant role in OPSCCs, 
we also accounted for its role in the multivariate regression. A recent study by Lassig et 
al. found no survival difference between their young and older patient cohorts with 
OPSCCs.32 While Lassig’s study utilized a similar methodology of matched pair analysis, 
their sample size of 87 patients per cohort may explain their lack of significant finding. In 
comparison, our OPSCC cohort included over 700 patients in each age group. Age, 





risk serotype and young age significantly diminishes the chance of death by 
approximately 60% and 44% when compared to HPV-negative and old age respectively).  
 
Finally, although literature has been inconclusive on the difference in survival between 
young and older patients in head and neck cancer, evidence from the Lassig study found 
that young patients are more likely to undergo neck dissection and thus receive more 
aggressive approach.32 In a deep-dive analysis (results not shown) of patients with both 
OC and OP SCCs in the post-matched cohorts, we found that younger patients were 
statistically significantly more likely to receive a neck dissection compared to the older 
cohort (OC: 48.7% vs. 45.3% p=0.041; OP 48.6% vs. 40.5% p=0.005). It is unknown 
whether this more aggressive approach is the cause for the improved OS among young 
patients in our study as neck dissections together with the surgical resection are bucketed 
into the ‘surgery’ treatment group. This is perhaps an interesting topic that warrants 
further investigation.  
 
Limitations associated with the NCDB  
The NCDB database, as a source, has well-documented limitations.90 We were unable to 
account for every variable that may influence survival (e.g. alcohol, tobacco use, and 
other comorbidities), as these data were not captured by NCDB. In addition, the database 
does not capture other causes of OC and OP cancers that may influence survival. 
Specifically, studies have shown that patients with cancer from previous leukoplakia91 or 
oral mucositis92 leading to earlier cancer detection is associated with improved survival, 





The type of testing (PCR, ISH for HPV DNA vs. p16) for HPV status may vary 
depending on each institution and reporting agency. Furthermore, the source of the 
sample may not necessarily derive from the primary site. There are likely low rates of 
misclassification due to the nature of the registry of the data; however, any 
misclassification is likely to have been evenly distributed across our four subgroups. Our 
retrospective study focuses on OS, not cancer-specific survival. The absence of cause-
specific survival data in NCDB makes in plausible that other causes of death such as 
treatment derived toxicities, secondary primary cancer and comorbid cardiovascular, 
pulmonary and metabolic syndrome causes which are more prominent in men may 
contribute to the difference in mortality seen between the two sexes. In addition, other 
general cancer risk factors such as tobacco and alcohol as well as high-risk sex behavior 
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Table 1. Patient Characteristics Among Those with Oropharyngeal SCC by HPV Status 
 
HPV- HPV+  
   Count % Count % P-Value 
Average Age (years) 60.95 58.83 <0.001 
Sex <0.001 
 
Male 6056 76.3% 11808 86.2% 
 
Female 1877 23.7% 1886 13.8% 
Ethnicity <0.001 
 
White 6733 85.6% 12714 93.7% 
 
Black 952 12.1% 645 4.8% 
 
American Indian/Eskimo 20 0.3% 27 0.2% 
 
Asian/Pacific Islander 119 1.5% 131 1.0% 
 
Other 43 0.5% 57 0.4% 
Charlson/Deyo Score <0.001 
 
0 6294 79.3% 11487 83.9% 
 
1 1246 15.7% 1758 12.8% 
 
2 393 5.0% 449 3.3% 
Primary Payer <0.001 
 
Not Insured 494 6.3% 508 3.7% 
 
Private Insurance/Managed Care 3333 42.8% 8253 60.9% 
 
Medicaid 943 12.1% 915 6.8% 
 
Medicare 2871 36.9% 3574 26.4% 
 
Other Government 150 1.9% 302 2.2% 
Median Income Quartiles: 2008-2012 <0.001 
 
<$38,000 1573 19.9% 1746 12.8% 
 
$38,000-$47,999 1786 22.6% 2878 21.1% 
 
$48,000-$62,999 2097 26.6% 3753 27.5% 
 
$63,000 + 2430 30.8% 5273 38.6% 
Urban/Rural 0.23 
 
Metro 6592 85.2% 11399 85.3% 
 
Urban 1040 13.4% 1747 13.1% 
 
Rural 108 1.4% 224 1.7% 
Facility Type <0.001 
 
Community Cancer Program 690 8.8% 871 6.5% 
 
Comprehensive Community Cancer Program 2785 35.6% 4315 32.0% 
 
Academic/Research Program 3469 44.4% 6717 49.7% 
 
Integrated Network Cancer Program 870 11.1% 1599 11.8% 
 
Other specified types of cancer programs 0 0.0% 0 0.0% 
Facility Location <0.001 
 
Northeast 1621 20.7% 2859 21.2% 
 
South 3158 40.4% 4525 33.5% 
 
Midwest 1875 24.0% 3689 27.3% 
 
West 1160 14.8% 2429 18.0% 
Primary Treatment <0.001 
 
No treatment 376 4.7% 241 1.8% 
 
Radiation only 694 8.7% 1026 7.5% 
 
Radiation and chemotherapy 4575 57.7% 8196 59.9% 
 
Surgery and radiation 334 4.2% 881 6.4% 
 
Surgery, chemotherapy and radiation 935 11.8% 2368 17.3% 
 
Surgery only 682 8.6% 727 5.3% 
 
Chemotherapy only 337 4.2% 255 1.9% 
Clinical T Stage <0.001 
 
0 22 0.3% 98 0.7% 
 
1 1649 21.0% 3807 28.0% 
 
2 2768 35.2% 5604 41.1% 
 
3 1658 21.1% 2179 16.0% 
 
4 1560 19.8% 1544 11.3% 
 
X 208 2.6% 387 2.8% 
Clinical N Stage <0.001 
 
0 2004 25.3% 1654 12.1% 
 
1 1341 17.0% 2298 16.8% 
 
2 4175 52.8% 9111 66.6% 
 
3 343 4.3% 571 4.2% 
 
X 47 0.6% 36 0.3% 
Grade <0.001 
 
Well differentiated 437 7.2% 280 2.8% 
 
Moderately differentiated 3237 53.1% 4130 40.8% 
 
Poorly differentiated 2387 39.2% 5606 55.4% 






Table 2. Patient Characteristics Among Those with Hypopharyngeal SCC by HPV Status 
 
HPV- HPV+  
   Count % Count % P-Value 
Average Age (years) 63.53  61.29  0.005 
Sex     0.11 
 
Male 1288 80.2% 274 84.0%  
 
Female 317 19.8% 52 16.0%  
Ethnicity     <0.001 
 
White 1299 81.2% 293 90.7%  
 
Black 253 15.8% 23 7.1%  
 
American Indian/Eskimo 8 0.5% 0 0.0%  
 
Asian/Pacific Islander 30 1.9% 7 2.2%  
 
Other 9 0.6% 0 0.0%  
Charlson/Deyo Score     0.07 
 
0 1182 73.6% 257 78.8%  
 
1 326 20.3% 58 17.8%  
 
2 97 6.0% 11 3.4%  
Primary Payer     <0.001 
 
Not Insured 79 5.0% 13 4.0%  
 
Private Insurance/Managed Care 498 31.5% 154 47.5%  
 
Medicaid 246 15.6% 32 9.9%  
 
Medicare 725 45.9% 115 35.5%  
 
Other Government 33 2.1% 10 3.1%  
Median Income Quartiles: 2008-2012     0.01 
 
<$38,000 335 20.9% 41 12.6%  
 
$38,000-$47,999 378 23.6% 79 24.3%  
 
$48,000-$62,999 406 25.3% 100 30.8%  
 
$63,000 + 483 30.1% 105 32.3%  
Urban/Rural     0.17 
 
Metro 1349 85.8% 273 86.4%  
 
Urban 204 13.0% 35 11.1%  
 
Rural 20 1.3% 8 2.5%  
Facility Type     0.47 
 
Community Cancer Program 128 8.0% 23 7.1%  
 
Comprehensive Community Cancer Program 544 34.1% 118 36.5%  
 
Academic/Research Program 754 47.3% 156 48.3%  
 
Integrated Network Cancer Program 169 10.6% 26 8.0%  
 
Other specified types of cancer programs 0 0.0% 0 0.0%  
Facility Location     <0.001 
 
Northeast 375 23.5% 83 25.7%  
 
South 620 38.9% 113 35.0%  
 
Midwest 389 24.4% 56 17.3%  
 
West 211 13.2% 71 22.0%  
Primary Treatment     0.02 
 
No treatment 105 6.5% 12 3.7%  
 
Radiation only 174 10.8% 41 12.6%  
 
Radiation and chemotherapy 930 57.9% 201 61.7%  
 
Surgery and radiation 44 2.7% 9 2.8%  
 
Surgery, chemotherapy and radiation 131 8.2% 37 11.3%  
 
Surgery only 132 8.2% 16 4.9%  
 
Chemotherapy only 89 5.5% 10 3.1%  
Clinical T Stage     0.01 
 
0 2 0.1% 3 0.9%  
 
1 243 15.2% 49 15.2%  
 
2 525 32.9% 119 37.0%  
 
3 414 26.0% 83 25.8%  
 
4 385 24.2% 58 18.0%  
 
X 25 1.6% 10 3.1%  
Clinical N Stage     0.003 
 
0 521 32.5% 73 22.5%  
 
1 239 14.9% 57 17.5%  
 
2 738 46.0% 174 53.5%  
 
3 92 5.7% 21 6.5%  
 
X 14 0.9% 0 0.0%  
Grade     0.14 
 
Well differentiated 77 6.2% 9 3.7%  
 
Moderately differentiated 702 56.1% 124 51.5%  
 
Poorly differentiated 465 37.1% 106 44.0%  






Table 3. Patient Characteristics Among Those with Oral Cavity SCC by HPV Status 
 
HPV- HPV+  
   Count % Count % P-Value 
Average Age (years) 62.40  59.09  <0.001 
Sex     <0.001 
 
Male 4700 59.8% 884 72.5%  
 
Female 3160 40.2% 336 27.5%  
Ethnicity     0.08 
 
White 6870 88.1% 1100 90.8%  
 
Black 589 7.6% 69 5.7%  
 
American Indian/Eskimo 22 0.3% 3 0.2%  
 
Asian/Pacific Islander 254 3.3% 29 2.4%  
 
Other 65 0.8% 10 0.8%  
Charlson/Deyo Score     0.13 
 
0 6041 76.9% 948 77.7%  
 
1 1389 17.7% 222 18.2%  
 
2 430 5.5% 50 4.1%  
Primary Payer     <0.001 
 
Not Insured 368 4.8% 74 6.1%  
 
Private Insurance/Managed Care 3132 40.5% 565 46.8%  
 
Medicaid 775 10.0% 120 10.0%  
 
Medicare 3330 43.1% 417 34.6%  
 
Other Government 123 1.6% 30 2.5%  
Median Income Quartiles: 2008-2012     0.25 
 
<$38,000 1355 17.3% 184 15.2%  
 
$38,000-$47,999 1896 24.2% 299 24.6%  
 
$48,000-$62,999 2113 27.0% 349 28.7%  
 
$63,000 + 2472 31.5% 382 31.5%  
Urban/Rural     0.04 
 
Metro 6378 83.2% 1028 85.9%  
 
Urban 1169 15.3% 149 12.4%  
 
Rural 116 1.5% 20 1.7%  
Facility Type     0.15 
 
Community Cancer Program 462 6.2% 84 7.3%  
 
Comprehensive Community Cancer Program 2049 27.4% 314 27.4%  
 
Academic/Research Program 4130 55.2% 642 56.0%  
 
Integrated Network Cancer Program 838 11.2% 107 9.3%  
 
Other specified types of cancer programs 0 0.0% 0 0.0%  
Facility Location     0.08 
 
Northeast 1657 22.2% 242 21.1%  
 
South 2674 35.8% 376 32.8%  
 
Midwest 1942 26.0% 327 28.5%  
 
West 1206 16.1% 202 17.6%  
Primary Treatment     <0.001 
 
No treatment 283 3.6% 40 3.3%  
 
Radiation only 499 6.3% 82 6.7%  
 
Radiation and chemotherapy 1073 13.7% 331 27.1%  
 
Surgery and radiation 969 12.3% 137 11.2%  
 
Surgery, chemotherapy and radiation 1214 15.4% 201 16.5%  
 
Surgery only 3692 47.0% 403 33.0%  
 
Chemotherapy only 130 1.7% 26 2.1%  
Clinical T Stage     0.001 
 
0 13 0.2% 4 0.3%  
 
1 2871 37.7% 380 32.3%  
 
2 2323 30.5% 378 32.1%  
 
3 777 10.2% 128 10.9%  
 
4 1590 20.9% 272 23.1%  
 
X 48 0.6% 16 1.4%  
Clinical N Stage     <0.001 
 
0 5227 66.7% 618 50.8%  
 
1 884 11.3% 176 14.5%  
 
2 1589 20.3% 399 32.8%  
 
3 71 0.9% 17 1.4%  
 
X 65 0.8% 7 0.6%  
Grade     <0.001 
 
Well differentiated 1624 23.4% 148 14.8%  
 
Moderately differentiated 4119 59.3% 565 56.6%  
 
Poorly differentiated 1188 17.1% 279 28.0%  







Table 4. Patient Characteristics Among Those with Larynx SCC by HPV Status 
 
HPV- HPV+  
   Count % Count % P-Value 
Average Age (years) 64.12  59.58  0.003 
Sex     <0.001 
 
Male 5309 78.3% 661 70.2%  
 
Female 1475 21.7% 280 29.8%  
Ethnicity     0.00 
 
White 5602 83.2% 812 87.2%  
 
Black 958 14.2% 102 11.0%  
 
American Indian/Eskimo 20 0.3% 6 0.6%  
 
Asian/Pacific Islander 102 1.5% 8 0.9%  
 
Other 49 0.7% 3 0.3%  
Charlson/Deyo Score     0.39 
 
0 4785 70.5% 684 72.7%  
 
1 1509 22.2% 193 20.5%  
 
2 490 7.2% 64 6.8%  
Primary Payer     <0.001 
 
Not Insured 366 5.5% 58 6.2%  
 
Private Insurance/Managed Care 2175 32.6% 376 40.5%  
 
Medicaid 853 12.8% 107 11.5%  
 
Medicare 3164 47.5% 374 40.3%  
 
Other Government 109 1.6% 14 1.5%  
Median Income Quartiles: 2008-2012     0.31 
 
<$38,000 1499 22.2% 193 20.6%  
 
$38,000-$47,999 1798 26.6% 242 25.8%  
 
$48,000-$62,999 1678 24.8% 258 27.5%  
 
$63,000 + 1789 26.4% 244 26.0%  
Urban/Rural     0.17 
 
Metro 5613 84.7% 760 82.4%  
 
Urban 914 13.8% 143 15.5%  
 
Rural 102 1.5% 19 2.1%  
Facility Type     0.09 
 
Community Cancer Program 658 9.8% 75 8.7%  
 
Comprehensive Community Cancer Program 2512 37.4% 358 41.3%  
 
Academic/Research Program 2855 42.5% 360 41.5%  
 
Integrated Network Cancer Program 687 10.2% 74 8.5%  
 
Other specified types of cancer programs 0 0.0% 0 0.0%  
Facility Location     0.24 
 
Northeast 1604 23.9% 223 25.7%  
 
South 2575 38.4% 310 35.8%  
 
Midwest 1653 24.6% 206 23.8%  
 
West 880 13.1% 128 14.8%  
Primary Treatment     <0.001 
 
No treatment 451 6.6% 40 4.3%  
 
Radiation only 1897 28.0% 247 26.2%  
 
Radiation and chemotherapy 2279 33.6% 364 38.7%  
 
Surgery and radiation 604 8.9% 63 6.7%  
 
Surgery, chemotherapy and radiation 455 6.7% 79 8.4%  
 
Surgery only 913 13.5% 130 13.8%  
 
Chemotherapy only 185 2.7% 18 1.9%  
Clinical T Stage     0.001 
 
0 7 0.1% 2 0.2%  
 
1 2120 32.8% 227 25.4%  
 
2 1639 25.3% 262 29.3%  
 
3 1694 26.2% 260 29.1%  
 
4 968 15.0% 135 15.1%  
 
X 39 0.6% 7 0.8%  
Clinical N Stage     <0.001 
 
0 4589 67.9% 535 57.0%  
 
1 640 9.5% 101 10.8%  
 
2 1369 20.2% 273 29.1%  
 
3 98 1.4% 22 2.3%  
 
X 65 1.0% 7 0.7%  
Grade     <0.001 
 
Well differentiated 820 15.6% 81 11.1%  
 
Moderately differentiated 3282 62.4% 447 61.1%  
 
Poorly differentiated 1142 21.7% 200 27.4%  






Table 5. Patient Characteristics Among Those with Sinonasal Tract SCC by HPV Status 
 
HPV- HPV+  
   Count % Count % P-Value 
Average Age (years) 65.02  60.66  0.298 
Sex     0.07 
 
Male 284 64.0% 99 72.3%  
 
Female 160 36.0% 38 27.7%  
Ethnicity     0.24 
 
White 353 80.2% 118 86.8%  
 
Black 62 14.1% 9 6.6%  
 
American Indian/Eskimo 4 0.9% 1 0.7%  
 
Asian/Pacific Islander 18 4.1% 7 5.1%  
 
Other 3 0.7% 1 0.7%  
Charlson/Deyo Score     0.87 
 
0 336 75.7% 103 75.2%  
 
1 78 17.6% 23 16.8%  
 
2 30 6.8% 11 8.0%  
Primary Payer     0.04 
 
Not Insured 21 4.8% 4 2.9%  
 
Private Insurance/Managed Care 156 35.8% 60 43.8%  
 
Medicaid 31 7.1% 17 12.4%  
 
Medicare 223 51.1% 53 38.7%  
 
Other Government 5 1.1% 3 2.2%  
Median Income Quartiles: 2008-2012     0.15 
 
<$38,000 104 23.6% 22 16.1%  
 
$38,000-$47,999 105 23.8% 42 30.7%  
 
$48,000-$62,999 121 27.4% 42 30.7%  
 
$63,000 + 111 25.2% 31 22.6%  
Urban/Rural     0.27 
 
Metro 357 82.8% 117 88.6%  
 
Urban 68 15.8% 14 10.6%  
 
Rural 6 1.4% 1 0.8%  
Facility Type     0.68 
 
Community Cancer Program 33 7.7% 7 5.3%  
 
Comprehensive Community Cancer Program 120 28.1% 41 31.1%  
 
Academic/Research Program 220 51.5% 70 53.0%  
 
Integrated Network Cancer Program 54 12.6% 14 10.6%  
 
Other specified types of cancer programs 0 0.0% 0 0.0%  
Facility Location     0.17 
 
Northeast 82 19.2% 33 25.0%  
 
South 185 43.3% 47 35.6%  
 
Midwest 88 20.6% 23 17.4%  
 
West 72 16.9% 29 22.0%  
Primary Treatment     0.85 
 
No treatment 31 7.0% 6 4.4%  
 
Radiation only 52 11.7% 16 11.7%  
 
Radiation and chemotherapy 92 20.7% 32 23.4%  
 
Surgery and radiation 80 18.0% 30 21.9%  
 
Surgery, chemotherapy and radiation 72 16.2% 20 14.6%  
 
Surgery only 104 23.4% 29 21.2%  
 
Chemotherapy only 13 2.9% 4 2.9%  
Clinical T Stage     0.011 
 
0 2 0.5% 0 0.0%  
 
1 107 24.7% 30 22.7%  
 
2 54 12.4% 30 22.7%  
 
3 73 16.8% 26 19.7%  
 
4 198 45.6% 45 34.1%  
 
X 0 0.0% 1 0.8%  
Clinical N Stage     0.99 
 
0 352 79.3% 106 77.9%  
 
1 28 6.3% 9 6.6%  
 
2 51 11.5% 16 11.8%  
 
3 2 0.5% 1 0.7%  
 
X 11 2.5% 4 2.9%  
Grade     0.01 
 
Well differentiated 53 14.6% 4 3.3%  
 
Moderately differentiated 166 45.9% 62 51.7%  
 
Poorly differentiated 138 38.1% 52 43.3%  






Table 6. Patient Characteristics Among Those with Nasopharyngeal SCC by HPV Status 
 
HPV- HPV+  
   Count % Count % P-Value 
Average Age (years)  56.27  56.21 <0.001 
Sex     0.25 
 
Male 466 68.5% 235 72.1%  
 
Female 214 31.5% 91 27.9%  
Ethnicity     <0.001 
 
White 458 67.4% 283 87.6%  
 
Black 99 14.6% 22 6.8%  
 
American Indian/Eskimo 3 0.4% 0 0.0%  
 
Asian/Pacific Islander 111 16.3% 17 5.3%  
 
Other 9 1.3% 1 0.3%  
Charlson/Deyo Score     0.80 
 
0 554 81.5% 266 81.6%  
 
1 96 14.1% 43 13.2%  
 
2 30 4.4% 17 5.2%  
Primary Payer        0.25 
 
Not Insured 51 7.6% 18 5.6%  
 
Private Insurance/Managed Care 327 49.0% 180 55.7%  
 
Medicaid 91 13.6% 34 10.5%  
 
Medicare 185 27.7% 86 26.6%  
 
Other Government 14 2.1% 5 1.5%  
Median Income Quartiles: 2008-2012     0.18 
 
<$38,000 136 20.0% 48 14.7%  
 
$38,000-$47,999 157 23.1% 87 26.7%  
 
$48,000-$62,999 171 25.2% 89 27.3%  
 
$63,000 + 215 31.7% 102 31.3%  
Urban/Rural     0.01 
 
Metro 588 88.8% 267 84.0%  
 
Urban 72 10.9% 44 13.8%  
 
Rural 2 0.3% 7 2.2%  
Facility Type     0.41 
 
Community Cancer Program 49 8.1% 30 9.8%  
 
Comprehensive Community Cancer Program 219 36.3% 96 31.3%  
 
Academic/Research Program 267 44.3% 148 48.2%  
 
Integrated Network Cancer Program 68 11.3% 33 10.7%  
 
Other specified types of cancer programs 0 0.0% 0 0.0%  
Facility Location     0.61 
 
Northeast 121 20.1% 62 20.2%  
 
South 228 37.8% 106 34.5%  
 
Midwest 142 23.5% 84 27.4%  
 
West 112 18.6% 55 17.9%  
Primary Treatment        0.17 
 
No treatment 45 6.6% 11 3.4%  
 
Radiation only 36 5.3% 22 6.7%  
 
Radiation and chemotherapy 506 74.4% 248 76.1%  
 
Surgery and radiation 9 1.3% 4 1.2%  
 
Surgery, chemotherapy and radiation 34 5.0% 23 7.1%  
 
Surgery only 12 1.8% 2 0.6%  
 
Chemotherapy only 38 5.6% 16 4.9%  
Clinical T Stage     0.01 
 
0 1 0.1% 1 0.3%  
 
1 205 30.3% 73 22.6%  
 
2 140 20.7% 72 22.3%  
 
3 149 22.0% 62 19.2%  
 
4 161 23.8% 109 33.7%  
 
X 20 3.0% 6 1.9%  
Clinical N Stage     0.001 
 
0 175 25.8% 79 24.3%  
 
1 163 24.0% 88 27.1%  
 
2 233 34.3% 136 41.8%  
 
3 102 15.0% 19 5.8%  
 
X 6 0.9% 3 0.9%  
Grade     <0.001 
 
Well differentiated 21 4.2% 5 2.1%  
 
Moderately differentiated 119 23.9% 72 30.8%  
 
Poorly differentiated 280 56.3% 150 64.1%  





Table 7. 5-year unadjusted survival rates by HPV status and cancer sub-site 
Sub-site HPV+ HPV- Difference in survival 
(95%CI) 
Oropharynx 77.6% 50.7% 26.9% (25.6%-28.2%) 
Hypopharynx 52.2% 28.8% 23.4% (17.5%-29.3%) 
Oral Cavity 59.4% 53.1% 6.3% (3.3%-9.3%) 
Larynx 57.2% 48.7% 8.5% (5.1%-11.9%) 
Sinonasal tract 63.1% 45.1% 18% (8.7%-27.3%) 







Table 8. Cox Proportional Hazards Regression Analysis for Patients with Oropharyngeal SCC 
HR (95% CI) 
Mean Age 1.01 (1.01-1.02) 
Sex 
Men 1 
Women 1.09 (1.00-1.19) 
Ethnicity 
White 1 
Black 1.05 (0.94-1.17) 
American Indian/Eskimo 0.40 (0.13-1.25) 
Asian/Pacific Islander 0.68 (0.47-0.97) 
Other 1.06 (0.58-1.92) 
T Stage 
T0 1 
T1 1.76 (0.65-4.73) 
T2 2.71 (1.01-7.25) 
T3 4.45 (1.66-11.9) 
T4 6.43 (2.40-17.2) 
TX 3.29 (1.20-8.98) 
N Stage 
N0 1 
N1 0.87 (0.77-0.99) 
N2 1.10 (0.99-1.21) 
N3 1.84 (1.58-2.15) 
NX 1.25 (0.82-1.91) 
Charleson/Deyo Score 
0 1 
1 1.35 (1.24-1.48) 
2 1.62 (1.41-1.86) 
HPV Status   
HPV- 1 
HPV High Risk 0.44 (0.41-0.47) 
Insurance Status 
Not Insured 1 
Private Insurance/Managed Care 0.57 (0.49-0.66) 
Medicaid 1.12 (0.96-1.31) 
Medicare 0.97 (0.83-1.13) 
Other Government 0.99 (0.76-1.29) 
Median Income Quartiles: 2008-2012 
<$38,000 1 
$38,000-$47,999 0.89 (0.80-0.98) 
$48,000-$62,999 0.81 (0.73-0.90) 
$63,000 + 0.69 (0.62-0.77) 
Treatment Group 
No treatment 1 
Radiation only 0.41 (0.34-0.50) 
Radiation and chemotherapy 0.26 (0.22-0.30) 
Surgery and radiation 0.19 (0.14-0.24) 
Surgery, chemotherapy and radiation 0.26 (0.22-0.31) 
Surgery only 0.32 (0.26-0.40) 







Table 9. Cox Proportional Hazards Regression Analysis for Patients with Hypopharyngeal SCC 
HR (95% CI) 
Mean Age 1.02 (1.01-1.03) 
Sex 
Men 1 
Women 0.94 (0.77-1.16) 
Ethnicity 
White 1 
Black 1.13 (0.91-1.40) 
American Indian/Eskimo 0.83 (0.26-2.63) 
Asian/Pacific Islander 0.44 (0.18-1.08) 
Other 1.21 (0.29-4.93) 
T Stage 
T0 1 
T1 1.48 (0.19-11.0) 
T2 2.23 (0.30-16.4) 
T3 3.14 (0.42-23.1) 
T4 4.33 (0.58-31.9) 
TX 1.65 (0.19-13.6) 
N Stage 
N0 1 
N1 1.31 (1.01-1.69) 
N2 1.48 (1.21-1.82) 
N3 3.09 (2.22-4.31) 
NX 10.1 (3.58-28.9) 
Charleson/Deyo Score 
0 1 
1 1.06 (0.88-1.29) 
2 1.42 (1.04-1.95) 
HPV Status   
HPV- 1 
HPV High Risk 0.59 (0.45-0.77) 
Insurance Status 
Not Insured 1 
Private Insurance/Managed Care 0.57 (0.40-0.82) 
Medicaid 0.80 (0.55-1.15) 
Medicare 0.73 (0.50-1.06) 
Other Government 0.57 (0.30-1.05) 
Median Income Quartiles: 2008-2012 
<$38,000 1 
$38,000-$47,999 0.89 (0.71-1.12) 
$48,000-$62,999 0.93 (0.74-1.17) 
$63,000 + 0.73 (0.58-0.93) 
Treatment Group 
No treatment 1 
Radiation only 0.50 (0.34-0.72) 
Radiation and chemotherapy 0.27 (0.20-0.37) 
Surgery and radiation 0.17 (0.09-0.32) 
Surgery, chemotherapy and radiation 0.23 (0.15-0.34) 
Surgery only 0.29 (0.19-0.45) 







Table 10. Cox Proportional Hazards Regression Analysis for Patients with Oral Cavity SCC 
HR (95% CI) 
Mean Age 1.02 (1.02-1.02) 
Sex 
Men 1 
Women 0.85 (0.78-0.93) 
Ethnicity 
White 1 
Black 0.99 (0.84-1.15) 
American Indian/Eskimo 1.12 (0.50-2.52) 
Asian/Pacific Islander 0.95 (0.73-1.23) 
Other 0.55 (0.31-0.99) 
T Stage 
T0 1 
T1 0.41 (0.17-1.01) 
T2 0.72 (0.29-1.75) 
T3 0.98 (0.40-2.40) 
T4 1.14 (0.46-2.77) 
TX 1.10 (0.41-2.94) 
N Stage 
N0 1 
N1 1.49 (1.30-1.70) 
N2 1.62 (1.44-1.81) 
N3 1.94 (1.38-2.73) 
NX 1.23 (0.78-1.93) 
Charleson/Deyo Score 
0 1 
1 1.08 (0.96-1.21) 
2 1.47 (1.24-1.74) 
HPV Status   
HPV- 1 
HPV High Risk 0.76 (0.66-0.87) 
Insurance Status 
Not Insured 1 
Private Insurance/Managed Care 0.80 (0.65-0.98) 
Medicaid 1.31 (1.05-1.62) 
Medicare 1.04 (0.85-1.28) 
Other Government 1.09 (0.75-1.58) 
Median Income Quartiles: 2008-2012 
<$38,000 1 
$38,000-$47,999 0.88 (0.77-1.00) 
$48,000-$62,999 0.94 (0.83-1.07) 
$63,000 + 0.81 (0.71-0.92) 
Treatment Group 
No treatment 1 
Radiation only 0.50 (0.39-0.64) 
Radiation and chemotherapy 0.44 (0.35-0.54) 
Surgery and radiation 0.33 (0.26-0.41) 
Surgery, chemotherapy and radiation 0.44 (0.35-0.55) 
Surgery only 0.38 (0.31-0.46) 







Table 11. Cox Proportional Hazards Regression Analysis for Patients with Larynx SCC 
HR (95% CI) 
Mean Age 1.03 (1.02-1.03) 
Sex 
Men 1 
Women 0.81 (0.71-0.91) 
Ethnicity 
White 1 
Black 1.04 (0.91-1.20) 
American Indian/Eskimo 0.58 (0.18-1.82) 
Asian/Pacific Islander 0.86 (0.55-1.34) 
Other 0.45 (0.18-1.10) 
T Stage 
T0 1 
T1 1.03 (0.14-7.36) 
T2 1.73 (0.24-12.4) 
T3 2.18 (0.30-15.6) 
T4 2.98 (0.41-21.4) 
TX 3.23 (0.42-24.7) 
N Stage 
N0 1 
N1 1.29 (1.09-1.53) 
N2 1.72 (1.51-1.96) 
N3 3.28 (2.46-4.37) 
NX 2.29 (1.55-3.38) 
Charleson/Deyo Score 
0 1 
1 1.10 (0.98-1.24) 
2 1.58 (1.33-1.86) 
HPV Status   
HPV- 1 
HPV High Risk 0.71 (0.59-0.85) 
Insurance Status 
Not Insured 1 
Private Insurance/Managed Care 0.99 (0.78-1.24) 
Medicaid 1.34 (1.05-1.71) 
Medicare 1.10 (0.87-1.39) 
Other Government 0.93 (0.56-1.53) 
Median Income Quartiles: 2008-2012 
<$38,000 1 
$38,000-$47,999 1.03 (0.89-1.18) 
$48,000-$62,999 1.01 (0.87-1.16) 
$63,000 + 0.86 (0.74-1.00) 
Treatment Group 
No treatment 1 
Radiation only 0.34 (0.28-0.42) 
Radiation and chemotherapy 0.34 (0.28-0.41) 
Surgery and radiation 0.24 (0.18-0.31) 
Surgery, chemotherapy and radiation 0.32 (0.25-0.41) 
Surgery only 0.33 (0.26-0.42) 







Table 12. Cox Proportional Hazards Regression Analysis for Patients with Sinonasal SCC 
HR (95% CI) 
Mean Age 1.04 (1.02-1.05) 
Sex 
Men 1 
Women 0.79 (0.55-1.14) 
Ethnicity 
White 1 
Black 1.51 (0.97-2.35) 
American Indian/Eskimo 2.30 (0.67-7.83) 











N1 2.12 (1.16-3.86) 
N2 1.30 (0.76-2.22) 
N3 0.88 (0.11-6.91) 
NX 0.88 (0.31-2.47) 
Charleson/Deyo Score 
0 1 
1 1.35 (0.86-2.09) 
2 2.14 (1.24-3.69) 
HPV Status   
HPV- 1 
HPV High Risk 0.63 (0.39-1.01) 
Insurance Status 
Not Insured 1 
Private Insurance/Managed Care 1.24 (0.48-3.20) 
Medicaid 3.16 (1.13-8.81) 
Medicare 1.30 (0.48-3.50) 
Other Government 0.73 (0.07-6.73) 
Median Income Quartiles: 2008-2012 
<$38,000 1 
$38,000-$47,999 0.93 (0.58-1.48) 
$48,000-$62,999 1.27 (0.80-2.02) 
$63,000 + 1.01 (0.61-1.66) 
Treatment Group 
No treatment 1 
Radiation only 0.17 (0.08-0.39) 
Radiation and chemotherapy 0.24 (0.11-0.50) 
Surgery and radiation 0.11 (0.05-0.26) 
Surgery, chemotherapy and radiation 0.15 (0.06-0.34) 
Surgery only 0.23 (0.11-0.49) 
Chemotherapy Only 0.11 (0.03-0.36) 







Table 13. Cox Proportional Hazards Regression Analysis for Patients with Nasopharyngeal SCC 
HR (95% CI) 
Mean Age 1.03 (1.02-1.05) 
Sex 
Men 1 
Women 0.85 (0.61-1.17) 
Ethnicity 
White 1 
Black 1.06 (0.67-1.68) 
American Indian/Eskimo 1.30 (0.16-10.2) 




T1 0.17 (0.02-1.37) 
T2 0.19 (0.02-1.53) 
T3 0.25 (0.03-1.98) 
T4 0.43 (0.05-3.31) 
TX 0.26 (0.03-2.32) 
N Stage 
N0 1 
N1 0.76 (0.50-1.17) 
N2 1 (0.68-1.45) 
N3 1.49 (0.92-2.39) 
NX 1.23 (0.44-3.46) 
Charleson/Deyo Score 
0 1 
1 1.18 (0.81-1.73) 
2 1.73 (1.03-2.89) 
HPV Status   
HPV- 1 
HPV High Risk 1.03 (0.75-1.42) 
Insurance Status 
Not Insured 1 
Private Insurance/Managed Care 0.41 (0.24-0.70) 
Medicaid 0.61 (0.33-1.12) 
Medicare 0.57 (0.31-1.02) 
Other Government 1.23 (0.39-3.85) 
Median Income Quartiles: 2008-2012 
<$38,000 1 
$38,000-$47,999 0.83 (0.54-1.29) 
$48,000-$62,999 0.93 (0.61-1.42) 
$63,000 + 0.70 (0.46-1.07) 
Treatment Group 
No treatment 1 
Radiation only 0.27 (0.12-0.61) 
Radiation and chemotherapy 0.20 (0.11-0.34) 
Surgery and radiation 0.07 (0.00-0.57) 
Surgery, chemotherapy and radiation 0.29 (0.13-0.63) 
Surgery only 0.68 (0.23-2.00) 
Chemotherapy Only 1.09 (0.57-2.08) 
*Insufficient simple size for calculation 
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 Chemotherapy Only  220 1.9%   35 1.9%   262 4.3%   75 4.0%  






Table 15. Patient characteristics among those with oral cavity squamous cell carcinoma based on sex and HPV status  
  
Oral Cavity HPV-associated 
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Table 16. Cox proportional hazards regression analysis for patients with oropharyngeal squamous cell carcinoma  
  Oropharynx HPV-associated Oropharynx HPV - 
    HR (95% CI) P HR (95% CI) P 
Mean age  1.02 (1.01-1.03) <0.001 1.01 (1.00-1.02) <0.001 
Ethnicity 
White 1.00 1.00 
Black 0.86 (0.67-1.10) 0.25 1.14 (1.01-1.30) 0.03 
American Indian/Eskimo 0.61 (0.15-2.47) 0.49 0.22 (0.03-1.58) 0.13 
Asian/Pacific Islander 0.52 (0.24-1.10) 0.09 0.75 (0.50-1.14) 0.19 
Other 0.63 (0.15-2.52) 0.51 1.29 (0.67-2.49) 0.44 
Sex 
Men 1.00 1.00 
Women 0.93 (0.79-1.09) 0.412 1.15 (1.04-1.28) 0.004 
Charlson/Deyo Score 
0 1.0 1.0 
1 1.42 (1.23-1.65) <0.001 1.31 (1.17-1.46) <0.001 
2 1.97 (1.56-2.48) <0.001 1.49 (1.25-1.77) <0.001 
AJCC Clinical Staging 
T Staging 
T0 1.00 1.00 
T1 2.61 (0.64-10.5) 0.18 1.31 (0.32-5.30) 0.70 
T2 4.24 (1.05-17.0) 0.04 1.93 (0.48-7.79) 0.35 
T3 6.47 (1.60-26.1) 0.01 3.26 (0.81-13.1) 0.10 
T4 9.92 (2.45-40.0) 0.00 4.35 (1.08-17.5) 0.04 
TX 3.93 (0.93-16.4) 0.06 2.65 (0.64-10.9) 0.18 
N Staging 
N0 1.00 1.00 
N1 0.81 (0.64-1.01) 0.07 0.95 (0.82-1.10) 0.53 
N2 1.14 (0.95-1.37) 0.14 1.10 (0.98-1.24) 0.09 
N3 2.06 (1.58-2.67) <0.001 1.76 (1.45-2.15) <0.001 
NX 0.73 (0.29-1.83) 0.51 1.47 (0.91-2.36) 0.11 
Primary Site 
Base of Tongue 1.00 1.00 
Tonsil 1.03 (0.91-1.16) 0.63 0.87 (0.79-0.96) 0.01 
Other OP 1.48 (1.21-1.81) <0.001 1.15 (1.02-1.30) 0.02 
Insurance Status 
Not Insured 1.00 1.00 
Private Insurance/Managed Care 0.53 (0.41-0.68) <0.001 0.61 (0.51-0.72) <0.001 
Medicaid 1.04 (0.78-1.38) 0.77 1.11 (0.93-1.34) 0.23 
Medicare 0.99 (0.76-1.30) 0.98 0.94 (0.78-1.13) 0.55 
Other Government 0.96 (0.63-1.46) 0.85 0.96 (0.67-1.36) 0.83 
Median Income Quartiles 2008-2012 
<$38,000 1.00 1.00 
$38,000-$47,999 0.89 (0.75-1.06) 0.21 0.9 (0.79-1.02) 0.11 
$48,000-$62,999 0.78 (0.65-0.93) 0.01 0.83 (0.73-0.94) 0.01 
$63,000 + 0.65 (0.54-0.77) <0.001 0.73 (0.64-0.83) <0.001 
Treatment Group 
No treatment 1.00 1.00 
Radiation only 0.34 (0.24-0.48) <0.001 0.44 (0.35-0.54) <0.001 
Radiation and Chemo 0.22 (0.16-0.29) <0.001 0.27 (0.23-0.33) <0.001 
Surgery and Radiation 0.16 (0.10-0.24) <0.001 0.20 (0.14-0.28) <0.001 
Surgery, Chemotherapy and Radiation 0.21 (0.15-0.29) <0.001 0.29 (0.23-0.35) <0.001 
Surgery only 0.21 (0.14-0.32) <0.001 0.37 (0.29-0.47) <0.001 
Chemotherapy Only   1.08 (0.76-1.54) 0.64 0.94 (0.76-1.18) 0.64 






  Oral Cavity HPV-associated Oral Cavity HPV - 
    HR (95% CI) P HR (95% CI) P 
Mean age  1.02 (1.00-1.04) 0.010 1.02 (1.02-1.02) <0.001 
Ethnicity 
White 1.00 1.00 
Black 1.88 (1.14-3.11) 0.013 0.93 (0.79-1.09) 0.41 
American Indian/Eskimo * 1.18 (0.52-2.64) 0.68 
Asian/Pacific Islander 1.60 (0.64-4.00) 0.312 0.93 (0.71-1.22) 0.63 
Other 0.65 (0.09-4.78) 0.678 0.54 (0.30-0.99) 0.05 
Sex 
Men 1.00 1.00 
Women 0.71 (0.50-0.99) 0.048 0.87 (0.78-0.95) 0.004 
AJCC Clinical Staging 
T Staging 
T0 1.00 1.00 
T1 0.36 (0.07-1.65) 0.189 0.45 (0.14-1.43) 0.18 
T2 0.61 (0.13-2.80) 0.529 0.79 (0.25-2.49) 0.70 
T3 0.90 (0.19-4.21) 0.903 1.07 (0.34-3.38) 0.90 
T4 1.33 (0.29-5.98) 0.707 1.19 (0.37-3.73) 0.76 
TX 0.67 (0.11-4.00) 0.666 1.36 (0.39-4.70) 0.63 
N Staging 
N0 1.00 1.00 
N1 1.07 (0.70-1.63) 0.743 1.54 (1.34-1.77) <0.001 
N2 1.08 (0.75-1.55) 0.651 1.72 (1.52-1.94) <0.001 
N3 0.88 (0.26-2.93) 0.836 2.12 (1.49-3.03) <0.001 
NX 1.30 (0.17-9.88) 0.795 1.19 (0.75-1.89) 0.45 
Insurance Status 
Not Insured 1.00 1.00 
Private Insurance/Managed Care 0.74 (0.42-1.32) 0.319 0.81 (0.65-1.00) 0.06 
Medicaid 1.82 (0.96-3.43) 0.064 1.27 (1.00-1.60) 0.043 
Medicare 1.32 (0.72-2.41) 0.355 1.04 (0.83-1.30) 0.72 
Other Government 0.83 (0.31-2.19) 0.713 1.17 (0.78-1.76) 0.44 
Median Income Quartiles 2008-2012 
<$38,000 1.00 1.00 
$38,000-$47,999 1.38 (0.88-2.17) 0.160 0.84 (0.73-0.96) 0.02 
$48,000-$62,999 1.49 (0.96-2.33) 0.075 0.90 (0.79-1.03) 0.14 
$63,000 + 1.37 (0.87-2.16) 0.169 0.77 (0.67-0.88) <0.001 
Treatment Group 
No treatment 1.00 1.00 
Radiation only 0.56 (0.25-1.23) 0.151 0.49 (0.37-0.63) <0.001 
Radiation and Chemo 0.42 (0.22-0.82) 0.011 0.44 (0.35-0.55) <0.001 
Surgery and Radiation 0.23 (0.10-0.50) <0.001 0.33 (0.26-0.43) <0.001 
Surgery, Chemotherapy and Radiation 0.59 (0.30-1.15) 0.127 0.42 (0.33-0.53) <0.001 
Surgery only 0.48 (0.24-0.94) 0.033 0.37 (0.29-0.45) <0.001 
Chemotherapy Only   1.18 (0.49-2.82) 0.710 0.84 (0.61-1.16) 0.31 





Pre-Propensity Score Match Post-Propensity Score Match 
18-39yo 40+yo   18-39 years old 40+ years old   
    Mean Count Column (%) Mean Count Column (%) 
p-
value Mean Count Column (%) Mean Count Column (%) p-value 
Patient Age (years) 33.8 62.3 <0.001 32.5 57.8 <0.001 
Sex <0.001 0.81 
Male 
 
2,378  63.4%  110,343  72.8% 
 
1,980  56.4% 
 
1,970  56.1% 
Female 
 
1,371  36.6%  41,267  27.2% 
 
1,530  43.6% 
 
1,540  43.9% 
Race <0.001 0.052 
White 
 
3,180  86.2%  133,631  89.1% 
 
2,977  86.5% 
 
3,007  87.7% 
Black  285  7.7%  12,777  8.5%  238  6.9%  241  7.0% 
American Indian/Eskimo  12  0.3%  396  0.3%  14  0.4%  5  0.1% 
Asian/Pacific 
Islander  172  4.7%  2,410  1.6%  164  4.8%  126  3.7% 
Other  42  1.1%  797  0.5%  49  1.4%  49  1.4% 
Primary Payer <0.001 <0.001 




2,407  64.2%  64,180  42.3% 
 
2,483  70.7% 
 
2,510  71.5% 
Medicaid  599  16.0%  13,675  9.0%  466  13.3%  369  10.5% 
Medicare  158  4.2%  57,655  38.0%  131  3.7%  231  6.6% 
Other Government  49  1.3%  3,134  2.1%  49  1.4%  34  1.0% 
Insurance Status Unknown  155  4.1%  4,981  3.3%  85  2.4%  76  2.2% 
Charlson/Deyo Score <0.001 0.052 
0 
 
3,467  92.5%  122,153  80.6% 
 
3,246  92.5% 
 
3,252  92.6% 
1  234  6.2%  22,863  15.1%  222  6.3%  235  6.7% 
2  48  1.3%  6,594  4.3%  42  1.2%  23  0.7% 
Median Income Quartiles 2008-2012 0.036 0.841 
<$38,000  644  17.4%  28,122  18.8%  531  15.1%  554  15.8% 
$38,000-$47,999  885  23.9%  36,544  24.4%  820  23.4%  830  23.6% 
$48,000-$62,999  984  26.6%  39,799  26.6%  932  26.6%  912  26.0% 
$63,000 + 
 
1,188  32.1%  45,154  30.2% 
 
1,227  35.0% 
 
1,214  34.6% 
Urban/Rural 0.027 0.514 
Metro 
 
3,039  83.5%  120,145  81.9% 
 
2,908  84.5% 
 
2,872  83.5% 
Urban  538  14.8%  23,669  16.1%  481  14.0%  509  14.8% 






Table 19. Clinical, tumor characteristics by age (pre- and post-Propensity Score Match) 
Pre-Propensity Score Match Post-Propensity Score Match 
18-39 years old 40+ years old     18-39 years old 40+ years old 
Count 
Column 
(%) Count Column (%) p-value Count 
Column 
(%) Count Column (%) p-value 
Primary Sub-site <0.001 0.775 
Oral Cavity 2,482 66.2% 67,385 44.4% 2,728 77.7% 2,718 77.4% 
Oropharynx 1,267 33.8% 84,225 55.6% 782 22.3% 792 22.6% 
Clinical T Stage <0.001 0.937 
0 5 0.2% 413 0.3% 14 0.4% 13 0.4% 
1 1,388 45.4% 44,008 37.1% 1,930 55.0% 1,909 54.4% 
2 1,171 38.3% 49,610 41.9% 1,183 33.7% 1,209 34.4% 
3 428 14.0% 21,641 18.3% 336 9.6% 327 9.3% 
4 63 2.1% 2,829 2.4% 47 1.3% 52 1.5% 
Clinical N Stage <0.001 0.909 
0 1,928 68.1% 63,470 59.3% 2,676 76.2% 2,669 76.0% 
1 457 16.1% 21,940 20.5% 445 12.7% 456 13.0% 
2 331 11.7% 16,074 15.0% 300 8.5% 304 8.7% 
3 117 4.1% 5,614 5.2% 89 2.5% 81 2.3% 
Tumor Size <0.001 0.126 
Microscopic focus or foci only 31 0.9% 822 0.7% 35 1.1% 32 1.0% 
< 1 cm 603 18.4% 16,453 13.0% 821 25.2% 815 25.1% 
> 1 cm, < 2 cm 929 28.3% 30,074 23.8% 1,119 34.4% 1,070 32.9% 
> 2 cm, < 3 cm 708 21.6% 31,478 24.9% 654 20.1% 694 21.3% 
> 3 cm, < 4 cm 455 13.9% 23,131 18.3% 344 10.6% 356 10.9% 
> 4 cm, < 5 cm 278 8.5% 14,084 11.1% 160 4.9% 196 6.0% 
> 5cm 274 8.4% 10,118 8.0% 118 3.6% 87 2.7% 
HPV Status <0.001 0.399 
HPV Negative 505 13.5% 15,448 10.2% 423 12.1% 476 13.6% 
Low Risk Strains 16 0.4% 782 0.5% 14 0.4% 12 0.3% 
High Risk Strains 266 7.1% 14,705 9.7% 183 5.2% 174 5.0% 
Unknown 2,962 79.0% 120,675 79.6% 2,890 82.4% 2,848 81.2% 
Primary Treatment <0.001 0.583 
No treatment 64 1.7% 5,749 3.8% 54 1.5% 58 1.7% 
Radiation only 68 1.8% 10,282 6.8% 61 1.7% 78 2.2% 
Radiation and Chemotherapy 767 20.5% 54,197 35.7% 339 9.7% 357 10.2% 
Surgery and Radiation 437 11.7% 14,154 9.3% 515 14.7% 488 13.9% 
Surgery and Chemo-radiation 935 24.9% 23,017 15.2% 534 15.2% 515 14.7% 
Surgery only 1,406 37.5% 40,064 26.4% 2,007 57.2% 2,014 57.4% 







Table 20. Tumor by oral cavity/oropharynx sub-site by age (pre- and post-Propensity Score Match) 
Pre-Propensity Score Match Post-Propensity Score Match 
18-39 years old 40+ years old     18-39 years old 40+ years old   
Count Column (%) Count Column (%) p-value Count Column (%) Count Column (%) p-value 
Primary Oral Cavity/Oropharynx Sub-site <0.001 <0.001 
Lip  187  5.0%  6,141  4.1%  219  6.2%  251  7.2% 
Base of Tongue  449  12.0% 
 
35,571  23.5%  313  8.9%  297  8.5% 
Tongue (excluding base) 
 
1,851  49.4% 
 
26,817  17.7% 
 
1,632  46.5% 
 
1,314  37.4% 
Gum  79  2.1%  6,783  4.5%  63  1.8%  154  4.4% 
Floor of Mouth  109  2.9% 
 
11,448  7.6%  83  2.4%  374  10.7% 
Palate  70  1.9%  6,128  4.0%  439  12.5%  272  7.7% 
Mouth-Other  186  5.0% 
 
10,068  6.6%  292  8.3%  353  10.1% 
Tonsil  715  19.1% 
 
38,495  25.4%  410  11.7%  422  12.0% 
  Other-Oropharynx  103  2.7% 
 








Table 21. Cox proportional hazards regression analysis by age grouping in oral cavity and oropharynx tumors 
 
 
 Oral Cavity Oropharynx 
    HR P-value   HR P-value 
Age 
Grouping 
40+ years old 1.00 1.00 
18-39 years old 0.58 <0.001 0.556 <0.001 
Sex 
Male 1.00 1.00 
Female 0.912 0.17 1.161 0.22 
HPV Status 
HPV Negative 1.00 1.00 
HPV Low Risk 0.962 0.957 0.826 0.795 
HPV High Risk 0.81 0.512 0.397 0.011 
HPV Unknown 1.089 0.47 0.767 0.201 
Primary Treatment Group 
No treatment 1.00 1.00 
Radiation only 0.878 0.639 0.399 0.007 
Radiation and Chemotherapy 0.597 0.032 0.364 <0.001 
Surgery and Radiation 0.368 <0.001 0.346 0.001 
Surgery and Chemo-radiation 0.474 0.001 0.351 <0.001 
Surgery only 0.222 <0.001 0.394 0.001 
Clinical T Staging 
1 1.00 1.00 
2 3.458 <0.001 1.65 0.001 
3 5.056 <0.001 3.111 <0.001 
4 7.554 <0.001 4.175 <0.001 
Clinical N Staging 
0 1.00 1.00 
1 1.534 <0.001 0.906 0.528 
2 1.395 0.018 0.849 0.339 
3 2.337 0.001 1.792 0.002 
Oral Cavity Sub-site 
Lip 1.00 - 
Tongue (excluding base) 1.283 0.099 - 
Gum 1.415 0.104 - 
Floor of Mouth 1.447 0.029 - 
Palate 0.871 0.44 - 
Mouth- Other 1.127 0.483 - 
Oropharynx Sub-site 
Base of Tongue - 1.00 
Tonsil - 0.707 0.006 
Oropharynx-Other - 1.224 0.266 
Race 
White 1.00 1.00 
Black 0.87 0.291 1.506 0.018 
American Indian/Eskimo 0.858 0.793 0.874 0.767 
Asian/Pacific Islander 0.871 0.44 0.94 0.917 
  Other 0.927 0.788   - - 
 
